Mitoxantrone 2 mg/ml solution is indicated in the treatment of metastatic breast cancer. Mitoxantrone 2 mg/ml solution is indicated in the treatment of non-Hodgkin's lymphoma. Mitoxantrone 2 mg/ml solution is indicated for the treatment and acute myeloid leukaemia (AML) in adults. Mitoxantrone 2 mg/ml solution in combination regimens is indicated in the remission-induction treatment of blast crisis in chronic myeloid leukaemia. Mitoxantrone 2 mg/ml solution is indicated in combination with corticosteroids for palliation (e.g. pain relief) related to advanced castrate resistant prostate cancer. Mitoxantrone 2 mg/ml solution is indicated for treatment of patients with highly active relapsing multiple sclerosis associated with rapidly evolving disability where no alternative therapeutic options exist (see sections 4.2, 4.4 and 5.1).
Onkotrone Injection is indicated for the treatment of: - Metastatic breast cancer - Non-Hodgkin's Lymphoma - Acute myeloid leukaemia (AML) in adults - In combination regimens is indicated in the remission-induction treatment of blast crisis in chronic myeloid leukaemia - In combination with corticosteroids for palliation (e.g. pain relief) related to advanced castrate resistant prostate cancer.
Background: Today, there are no recommendations on switching disease-modifying treatments (DMTs) in multiple sclerosis (MS).
Astellas has announced an open-label, multicentre, randomised Phase III study of gilteritinib versus salvage chemotherapy in patients with acute myeloid...
Fingolimod is indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult patients and paediatric patients aged 10 years and older: - Patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4.4 and 5.1). or - Patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more Gadolinium enhancing lesions on brain MRI or a significant increase in T2 lesion load as compared to a previous recent MRI.